Product Introduction
ADC Linkers (Antibody-Drug Conjugate Linkers) are crucial chemical components used in the development of Antibody-Drug Conjugates (ADCs), a class of targeted cancer therapies. ADCs combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs, enabling the targeted delivery of drugs directly to cancer cells while minimizing damage to healthy cells. The linker plays a pivotal role in this process, connecting the antibody to the drug and ensuring controlled drug release within the targeted cells. The design and functionality of ADC linkers are vital for the safety, efficacy, and stability of ADCs, making them a critical component in modern cancer treatment.
Product Advantages And Features
Targeted Drug Delivery
ADC linkers allow for precise delivery of cytotoxic drugs to cancer cells, significantly reducing collateral damage to healthy cells.
Controlled Drug Release
Depending on the linker type, drug release can be triggered by specific conditions in the cancer cell environment, ensuring the drug is released only when needed.
Improved Efficacy
By enhancing the potency of the drug directly to the target, ADC linkers improve the overall therapeutic effectiveness of the treatment.
Minimized Side Effects
Since ADC linkers reduce off-target drug release, patients experience fewer side effects compared to traditional chemotherapy.
Enhanced Stability
Modern ADC linkers ensure that the drug remains securely attached to the antibody during circulation, preventing premature drug release and ensuring the drug reaches its intended target.
Versatile Design
ADC linkers can be tailored to different drugs and antibodies, allowing for a wide range of applications in targeted cancer therapies.
Product Type
These linkers are designed to release the drug in response to specific intracellular conditions such as low pH, presence of enzymes (proteases), or reducing environments (glutathione). Cleavable linkers ensure the drug is released only inside the target cells. Common types include:
• Acid-labile linkers: Trigger drug release in acidic environments like those found in lysosomes.
• Disulfide linkers: Sensitive to reducing agents in the cytosol of cancer cells.
• Peptide-based linkers: Cleaved by specific enzymes overexpressed in tumor cells.
These linkers keep the drug attached to the antibody until the antibody is degraded inside the cell. The drug is only released after the entire ADC is broken down. Non-cleavable linkers provide greater stability in circulation and are less likely to cause off-target toxicity.
These linkers improve the solubility of the ADC, enhancing its distribution and reducing the risk of aggregation, which can lead to reduced efficacy and increased immunogenicity.
Used when a more stable attachment is required, these linkers can enhance the binding affinity between the drug and antibody, improving overall efficacy.
Designed for specific applications in which precise control over the release of the drug is needed, these linkers are activated only by non-native biochemical reactions in the target environment.
Application Of The Product
ADC linkers are essential for the following applications:
Cancer Therapy
ADCs are primarily used in oncology to deliver cytotoxic drugs directly to cancer cells, reducing the systemic toxicity commonly associated with chemotherapy.
Personalized Medicine
ADC linkers enable the development of therapies that are tailored to individual patients' cancer profiles, allowing for more effective and personalized treatment strategies.
Drug Development
ADC linkers are a key focus in pharmaceutical research and development as scientists seek to design better drug conjugates with higher specificity and potency.
Immunotherapy
ADC linkers play a role in combining targeted drug delivery with immunotherapeutic agents, enhancing the body's immune response against cancer cells.
Combination Therapies
ADCs with specialized linkers can be used in combination with other treatments, such as radiotherapy or immunotherapy, to enhance overall treatment efficacy.
Targeted Delivery of Other Therapeutics
Beyond cancer, ADC linkers are being researched for delivering drugs in autoimmune diseases and other conditions where targeted therapy is beneficial.
Material Of The Product
ADC linkers are made from a combination of organic molecules and chemical groups designed to react selectively and stably with antibodies and drugs:
PEG (Polyethylene Glycol): Used in hydrophilic linkers to improve solubility and reduce immunogenicity.
Disulfide Bonds: Common in cleavable linkers, these bonds are sensitive to reducing conditions in the target cells.
Peptide Sequences: Designed to be cleaved by specific enzymes, often used in peptide-based cleavable linkers for cancer applications.
Acid-labile Groups: Incorporated into linkers that release drugs in acidic environments like endosomes and lysosomes.
Hydrazones: Functional groups that are stable at neutral pH but cleaved in acidic conditions, making them suitable for tumor-targeting applications.
Spacer Molecules: Included to distance the drug from the antibody, minimizing steric hindrance and ensuring proper binding and release.
Production Process Or Procedure
The production of ADC linkers requires precise and sophisticated chemical synthesis, as they need to be highly specific and stable:
Precise Synthesis
ADC linkers are crafted through highly controlled organic synthesis techniques to ensure correct chemical structure and functionality
Quality Control
Every batch of ADC linkers undergoes rigorous testing for purity, reactivity, and stability to ensure that they perform as intended when conjugated to antibodies and drugs.
Stability Testing
ADC linkers are tested under various physiological conditions (e.g., pH, enzymatic exposure) to ensure that they remain stable during circulation and only release the drug in the target environment.
Conjugation Optimization
The process of conjugating the drug to the antibody via the linker is carefully optimized to maximize drug payload and minimize interference with the antibody's binding capacity.
Components Of The Product
Antibody Binding Site
The end of the linker that attaches to the monoclonal antibody, designed to be stable and non-disruptive to the antibody's function.
Drug Binding Site
The section of the linker that connects to the cytotoxic drug, often designed to release the drug under specific conditions in the target cells.
Spacer
A chemical structure that separates the drug and antibody, reducing steric hindrance and ensuring proper drug release.
Cleavable/Non-Cleavable Bond
Depending on the linker type, this bond determines how and when the drug is released, ensuring precise delivery within cancer cells.
Functional Groups
The specific chemical groups that allow for the selective attachment of the linker to the antibody and drug without disrupting their structures.
Product Maintenance And Precautions
ADC linkers should be stored in a cool, dry environment to prevent premature degradation. Proper labeling of containers is essential to ensure correct handling.
Regularly check the shelf life of ADC linkers to ensure they maintain their stability and effectiveness over time.
Wear appropriate personal protective equipment (PPE) when handling ADC linkers, as they are often sensitive to moisture and temperature changes.
Before conjugation, perform tests to ensure that the linker is compatible with the specific antibody and drug being used in the ADC formulation.
Routine quality checks are essential to ensure that ADC linkers maintain their chemical integrity during storage and handling.
Company Advantages
Our Focus on Quality & Customer Experience
We dedicate to delivering high-quality products and exceptional customer service beyond your expectation.
Comprehensive Product Range
Extensive catalog of over 27,000 chemicals for diverse industries, offering both standard compounds and specialized solutions.
Strong Industry Expertise
Our experienced diverse team provides expert guidance, staying current with industry trends to deliver optimal chemical solutions tailored to your needs.
Competitive Pricing & Reliability
Competitive pricing and reliable deliveries ensure cost-effective, efficient supply chains without compromising quality.
How To Collaborate With Us
Partnering with LEAPChem gives you access to the expertise of a leading company with 18 years of experience in the chemical industry. We offer over 27,000 chemical substances tailored to meet diverse needs. All our products adhere to industry standards and are accompanied by the necessary certifications.
We collaborate with a wide range of partners, including:
• Research Laboratories
• Pharmaceutical Companies
• Cosmetics Manufacturers
• Electronics Manufacturers
• Chemical Manufacturers
• Universities and Colleges Worldwide
• And more.
We specialize in helping our clients find the right chemical solutions tailored to their specific requirements. Additionally, we provide custom synthesis services to meet the unique needs of our partners. Whether you need bulk quantities for industrial processes or small batches for specialized applications, we've got you covered.
If you are looking for a reliable chemical supplier, we would be delighted to hear from you. Please send your inquiry or project details to sales@leapchem.com. Our professional team is eager to collaborate with you and help achieve your goals.
FAQ
Q: What are ADC linkers?
A: ADC linkers are chemical compounds that connect the antibody to the cytotoxic drug in Antibody-Drug Conjugates (ADCs), ensuring targeted drug delivery.
Q: Why are ADC linkers important in cancer therapy?
A: ADC linkers enable the precise delivery of potent cancer-killing drugs directly to cancer cells, minimizing damage to healthy tissues and reducing side effects.
Q: What is the difference between cleavable and non-cleavable linkers?
A: Cleavable linkers release the drug in response to specific conditions within cancer cells, while non-cleavable linkers require the entire ADC to be degraded within the cell for drug release.
Q: How does a cleavable linker work?
A: Cleavable linkers release the cytotoxic drug when they encounter specific intracellular conditions, such as low pH or the presence of certain enzymes.
Q: Are ADC linkers stable during circulation?
A: Yes, modern ADC linkers are designed to remain stable during circulation, only releasing the drug once inside the target cells.
Q: What materials are used to make ADC linkers?
A: ADC linkers are made from a combination of organic molecules, including disulfide bonds, peptides, hydrazones, and spacer molecules.
Q: How do non-cleavable linkers release the drug?
A: Non-cleavable linkers release the drug when the entire ADC is broken down inside the target cell, ensuring greater stability in the bloodstream.
Q: What role do spacer molecules play in ADC linkers?
A: Spacer molecules distance the drug from the antibody, preventing interference with the antibody's binding capacity and ensuring proper drug release.
Q: Can ADC linkers be customized?
A: Yes, ADC linkers can be tailored to specific antibodies, drugs, and release conditions, making them highly versatile in targeted therapy applications.
Q: How are ADC linkers tested for stability?
A: ADC linkers undergo extensive stability testing in various physiological conditions to ensure they perform as intended during treatment.
Q: Do ADC linkers reduce side effects in cancer treatment?
A: Yes, by ensuring the cytotoxic drug is only released within cancer cells, ADC linkers reduce off-target toxicity and minimize side effects.
Q: Are there other applications for ADC linkers besides cancer therapy?
A: While primarily used in oncology, ADC linkers are also being researched for targeted delivery in autoimmune diseases and other therapeutic areas.
| CAS No. | Product Name | ||
| Non-Cleavable Linker | |||
| 71875-81-5 | SMCC | ||
| 64987-85-5 | SMCC | ||
| 103750-03-4 | 5-Maleimidovalericacid-NHS | ||
| 80307-12-6 | GMBS | ||
| 55750-63-5 | EMCS | ||
| 55750-61-3 | N-SMP | ||
| 756525-99-2 | Mal-DPEG4-NHS | ||
| 1334177-86-4 | Mal-amido-PEG8-acid | ||
| 1599472-25-9 | Mal-PEG6-NHS ester | ||
| 1537892-36-6 | Mal-PEG3-NHS ester | ||
| 1807534-78-6 | Mal-PEG3-PFP ester | ||
| 1008402-79-6 | Bis(NHS)PEG9 | ||
| 756526-03-1 | Bis(NHS)PEG5 | ||
| 1314378-11-4 | NHS-PEG3-NHS | ||
| 1314378-16-9 | Bis-PEG3-NHS Ester | ||
| 65869-63-8 | Bis-PEG2-NHS Ester | ||
| 65869-64-9 | Bis-PEG1-NHS ester | ||
| 1312309-64-0 | Azido-PEG2-NHS ester | ||
| 478801-48-8 | 5-azidopentanoic acid N-hydroxysuccinimide ester | ||
| 943858-70-6 | succimimidyl-4-azidobutyrate | ||
| 824426-32-6 | NHS-Ac-N3 | ||
| 1421932-52-6 | endo-BCN-PEG4-PFP ester | ||
| 1421932-53-7 | endo-BCN-PEG2-PFP ester | ||
| 1425803-45-7 | 2,5-dioxopyrrolidin-1-yl 2-(cyclooct-2-ynyloxy)acetate | ||
| 1428629-70-2 | Propargyl-PEG4-NHS ester | ||
| 906564-59-8 | 5-hexynoic NHS ester | ||
| 132178-37-1 | 4-pentynoic acid succinimidyl ester | ||
| 1347750-81-5 | MAL-Di-EG-OPFP | ||
| 1263044-56-9 | Mal-PEG10-NHS | ||
| 1137109-22-8 | Maleimide-NH-PEG10-CH2CH2COONHS Ester | ||
| 756525-93-6 | Mal-PEG8-NHS | ||
| 1137109-21-7 | Mal-PEG6-NHS | ||
| 1315355-92-0 | Mal-PEG5-NHS | ||
| 1347750-84-8 | Maleimide-NH-PEG4-CH2CH2COOPFP Ester | ||
| 955094-26-5 | Mal-PEG2-NHS | ||
| 1260092-50-9 | Mal-PEG-NHS | ||
| 1415800-42-8 | Mal-PEG4-PFP | ||
| 1325208-25-0 | Mal-PEG4-NHS | ||
| 1807512-47-5 | Mal-PEG2-PFP | ||
| 1433997-01-3 | Mal-PEG2-NHS | ||
| Cleavable Linker (Chemically-Cleavable) | |||
| Acid-Cleavable | |||
| 65623-82-7 | 4-(4-Acetyl-phenoxy)-butyric acid | ||
| 60444-78-2 | 2,5-dioxopyrrolidin-1-yl 4-formylbenzoate | ||
| 1309460-27-2 | Ald-Ph-PEG4-acid | ||
| 1007215-91-9 | Ald-Ph-PEG3-acid | ||
| 1061569-06-9 | Ald-Ph-PEG2-acid | ||
| 1007215-94-2 | tert-butyl 1-(4-formylphenyl)-1-oxo-5,8,11-trioxa-2-azatridecan-13-oate | ||
| 1245813-70-0 | tert-butyl 1-(4-formylphenyl)-1-oxo-5,8,11,14,17,20,23,26,29,32,35-undecaoxa-2-azaheptatriacontan-37-ylcarbamate | ||
| 1337889-01-6 | N-(35-amino-3,6,9,12,15,18,21,24,27,30,33-undecaoxapentatriacontyl)-4-formylbenzamide | ||
| 1324007-10-4 | Ald-PEG4-PFP | ||
| 1353011-74-1 | Ald-PEG4-NHS ester | ||
| 1807521-07-8 | Ald-Ph-PEG2-NHS | ||
| Reductive-Cleavable | |||
| 68181-17-9 | SPDP | ||
| 890409-85-5 | 2,5-dioxopyrrolidin-1-yl 4-methyl-4-(pyridin-2-yldisulfanyl)pentanoate | ||
| 874302-76-8 | 4-nitrophenyl 2-(pyridin-2-yldisulfanyl)ethyl carbonate | ||
| 1252257-56-9 | SPDP-PEG8-NHS | ||
| 1305053-43-3 | Pyridin-2-yldisulfanyl-PEG4-NHS | ||
| 1824718-79-7 | N-succinimidyl-6-(2-pyridyldithio)capronate | ||
| 317331-86-5 | N-succinimidyl-5-(2-pyridyldithio)valerate | ||
| 663598-98-9 | 2,5-dioxopyrrolidin-1-yl 4-methyl-4-((5-nitropyridin-2-yl)disulfanyl)pentanoate | ||
| 1193111-39-5 | 1-(2,5-dioxopyrrolidin-1-yloxy)-1-oxo-4-(pyridin-2-yldisulfanyl)butane-2-sulfonic acid | ||
| 663598-85-4 | N-succinimidyl 4-(5-nitro-pyridin-2-yldithio)-pentanoate | ||
| 107348-47-0 | 2,5-dioxopyrrolidin-1-yl 3-(pyridin-2-yldisulfanyl)butanoate | ||
| 160580-70-1 | perfluorophenyl 3-(pyridin-2-yldisulfanyl)propanoate | ||
| 121115-30-8 | 2,5-dioxo-1-(3-(pyridin-2-yldisulfanyl)propanoyloxy)pyrrolidine-3-sulfonic acid | ||
| 1610769-13-5 | 4-((S)-2-((S)-2-amino-3-methylbutanamido)-5-ureidopentanamido)benzyl 2-(pyridin-2-yldisulfanyl)ethylcarbamate | ||
| Cleavable Linker (Enzyme-Cleavable) | |||
| Cathepsin Cleavable | |||
| 159857-81-5 | Mc-Val-Cit-PABC-PNP | ||
| 159857-79-1 | Val-cit-PAB-OH | ||
| 159858-22-7 | Fmoc-Val-Cit-PAB | ||
| 863971-53-3 | Fmoc-Val-Cit-PAB-PNP | ||
| 2149584-03-0 | Phe-Lys(Fmoc)-PAB | ||
| 1116085-99-4 | Phe-Lys(Trt)-PAB | ||
| 1160844-44-9 | Boc-Phe-(Alloc)Lys-PAB-PNP | ||
| 159857-90-6 | Cbz-Phe-(Alloc)Lys-PAB-PNP | ||
| 253863-34-2 | Aloc-D-Ala-Phe-Lys(Aloc)-PAB-PNP | ||
| 1116086-09-9 | Fmoc-Phe-Lys(Trt)-PAB-PNP | ||
| Fmoc-Gly3-Val-Cit-PAB-OH | |||
| Fmoc-Gly3-Val-Cit-PAB-PNP | |||
| Mc-Val-Cit-PABC-Diamine | |||
| Mc-PEG2-Val-Cit-PAB | |||
| DBCO-Val-Cit-PAB | |||
| Glycosidase-Cleavage | |||
| β-Glucuronic-PAB | |||
| β-Glucuronic-PAB-PNP | |||
| β-Galactose-PAB-PNP | |||
| Other Linkage | |||
| 142356-33-0 | 6-(Boc-amino)hexyl bromide | ||
| 622405-78-1 | m-PEG4-NHS ester | ||
| 1025796-31-9 | (S)-di-tert-butyl 2-(3-((S)-6-amino-1-tert-butoxy-1-oxohexan-2-yl)ureido)pentanedioate | ||
| 1026987-94-9 | (S)-5-tert-Butoxy-4-(3-((s)-1,5-di-tert-butoxy-1,5-dioxopentan-2-yl)ureido)-5-oxopentanoic Acid | ||
| 1127247-34-0 | m-PEG2-NHS ester | ||
| Linker Payload | |||
| 169869-90-3 | Exatecan Mesylate | ||
| 171335-80-1 | Exatecan | ||
| 1599440-33-1 | DXD | ||
| 66584-72-3 | Ansamitocin P-3 | ||
| 57103-68-1 | Ansamitocin P-0 | ||
| 139504-50-0 | DM1 | ||
| 796073-69-3 | DM4 | ||